PMID- 24848756
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20211021
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 74
IP  - 8
DP  - 2014 Jun
TI  - Luseogliflozin: first global approval.
PG  - 945-50
LID - 10.1007/s40265-014-0230-8 [doi]
AB  - Luseogliflozin [Lusefi((R)) (Japan)] is an orally active second-generation 
      sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho 
      Pharmaceutical for the treatment of patients with type 2 diabetes mellitus 
      (T2DM). The drug has received its first global approval for this indication in 
      Japan, either as monotherapy or in combination with other antihyperglycaemic 
      agents. This article summarises the milestones in the development of 
      luseogliflozin leading to this first approval for the treatment of T2DM.
FAU - Markham, Anthony
AU  - Markham A
AD  - Adis, Auckland, New Zealand.
FAU - Elkinson, Shelley
AU  - Elkinson S
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 506T60A25R (Sorbitol)
RN  - C596HWF74Z 
      (1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Drug Approval
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Japan
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - Sorbitol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic 
      use
EDAT- 2014/05/23 06:00
MHDA- 2015/06/16 06:00
CRDT- 2014/05/23 06:00
PHST- 2014/05/23 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - 10.1007/s40265-014-0230-8 [doi]
PST - ppublish
SO  - Drugs. 2014 Jun;74(8):945-50. doi: 10.1007/s40265-014-0230-8.